Elanco Strategy and Business Model

Executive Overview

Elanco is a pure-play animal health company that develops, manufactures, and markets medicines, parasiticides, vaccines, and productivity products for both companion animals and livestock. Headquartered in Greenfield, Indiana, the business traces its roots to Eli Lilly’s animal health operation, founded in 1954, and became a fully independent public company in 2019. As of Elanco’s 2023 Form 10-K, the company operated in more than 90 countries. Its portfolio spans pet brands such as Seresto, Advantage, Credelio, Galliprant, and Interceptor Plus, as well as farm-animal products including Rumensin and Experior. Revenue was about $4.4 billion in 2023.

Strategically, Elanco is trying to improve its mix toward faster-growing companion-animal categories while still protecting a meaningful, cash-generative farm-animal franchise. Public company communications through mid-2024 emphasized several themes: executing key pet-health launches, improving commercial performance in the base business, simplifying the portfolio, driving productivity across manufacturing and overhead, and reducing leverage. The announced February 2024 agreement to sell the aqua business to Merck Animal Health, if completed, would fit that logic by sharpening focus and providing cash for debt reduction. That makes Elanco not just a veterinary-pharma company, but a portfolio-management story shaped by product mix, channel execution, supply reliability, and capital discipline.

Elanco at a Glance

Logo
Common name	Elanco
Full legal name	Elanco Animal Health Incorporated
Headquarters	Greenfield, Indiana, United States
Ownership	Public company; widely held institutional ownership with no controlling shareholder disclosed
Ticker	ELAN
Exchange	NYSE - New York Stock Exchange
Market Cap	$11.58B
Revenue (FY2024)	$4.44B
Founding / major historical milestones	Founded in 1954 within Eli Lilly; initial public offering in 2018; fully separated from Eli Lilly in 2019; acquired Bayer Animal Health in 2020; announced sale of aqua business to Merck Animal Health in February 2024, subject to closing conditions
Industry or industries	Animal health; veterinary pharmaceuticals; companion-animal and livestock health
Key products or services	Companion-animal parasiticides and therapeutics; livestock health products, feed additives, vaccines, and productivity solutions
Geographic footprint	Global, with operations and sales in more than 90 countries as of 2023
Business segments as officially reported	One reportable segment: Animal Health; investors also commonly view the portfolio through Pet Health and Farm Animal categories
Company website	https://www.elanco.com

1. What Is the Strategy of Elanco?

1. 1a. What is the winning aspiration of Elanco?

   Elanco’s stated purpose is Food and Companionship Enriching Life. In practical strategic terms, winning means being a more focused, innovation-led animal health company with stronger exposure to companion-animal growth, more dependable profitability, and a healthier balance sheet than it had immediately after the Bayer Animal Health acquisition. In public communications through mid-2024, management tied success to executing new-product launches, improving the base business, expanding margins through productivity, and reducing leverage. That means Elanco’s aspiration is not just to be large; it is to become simpler, faster-growing, and financially more flexible.

   There is also a portfolio-quality element to the aspiration. Companion-animal products generally carry better growth and margin potential than many mature livestock categories, so part of “winning” for Elanco is mix improvement. The announced sale of the aqua business in February 2024 fits that logic: sharpen the portfolio, free cash for debt reduction, and concentrate resources where management believes the company can create more value.

2. 1b. Where does Elanco play?

   Elanco plays across two broad animal-health arenas: companion animals and farm animals. In companion animal health, it competes in flea-and-tick control, deworming, pain, dermatology, and other veterinary therapeutic categories sold through veterinarians, distributors, retail, and e-commerce channels. In farm animal health, it serves cattle, dairy, swine, poultry, and, as of early 2024, aquaculture, with products aimed at disease management, productivity, feed efficiency, and herd or flock performance.

   Geographically, Elanco plays globally. The United States is a critical market, but the company also has meaningful exposure across Europe, Latin America, and Asia-Pacific. Channel-wise, it competes in both prescription-oriented veterinary channels and consumer-facing pet retail. That breadth matters: Elanco is not confined to one species, one geography, or one route to market, but it is increasingly emphasizing the parts of the portfolio that can benefit from stronger brand pull and better recurring demand.

3. 1c. How does Elanco plan to win?

   Elanco’s path to winning is a mix of brand strength, veterinary science, focused innovation, and improved execution. In companion animal health, the company aims to win by offering products that veterinarians trust, pet owners repurchase, and retailers are willing to support. In farm animal health, the company wins when it can show producers a clear economic benefit through better animal performance, disease prevention, feed efficiency, or compliance with changing production standards.

   Public strategy signals through 2024 suggest four practical levers. First, launch and scale higher-value pet products. Second, defend and optimize established brands such as Seresto and Advantage. Third, simplify operations and remove cost from the larger post-Bayer footprint. Fourth, reshape the portfolio where needed, including divestitures, to improve focus and capital flexibility. In other words, Elanco is not trying to win only through discovery science; it is trying to win through better portfolio economics and better commercial execution.

4. 1d. What capabilities must Elanco have in place?

   To make that strategy work, Elanco needs several capabilities that are hard to fake. The first is animal-health research, development, and regulatory execution: getting products approved, keeping registrations current across countries, and converting pipeline assets into launches. The second is high-reliability manufacturing and quality management, because veterinary pharmaceuticals, feed additives, vaccines, and consumer pet products all require strict process control.

   The third is multi-channel commercial capability. Elanco must sell effectively to veterinary clinics, distributors, retailers, e-commerce platforms, and livestock producers, each of which buys differently. The fourth is brand management, especially in consumer-visible pet parasiticides. The fifth is capital and portfolio discipline: deciding which brands, categories, and assets deserve investment and which do not. Given the company’s post-Bayer history, integration, simplification, and debt management are strategic capabilities, not just finance tasks.

5. 1e. What management systems does Elanco require?

   Elanco needs management systems that fit a global, regulated, product-based business. That includes pharmacovigilance and product-safety monitoring, launch governance, inventory and demand-planning disciplines, pricing and gross-margin controls, and regulatory-quality systems that work across many countries and product types. Because portions of the business are seasonal, management also needs good visibility into channel inventory, not just shipments.

   Financial management systems are equally important. Public messaging through 2024 made clear that leverage, adjusted earnings, and cash generation remain central performance measures. Elanco therefore needs operating reviews that connect commercial performance, supply reliability, working capital, and debt reduction. The strategic test is straightforward: the systems must prevent the company from becoming a loose collection of acquired brands and instead keep it running as a focused animal-health portfolio.

2. What are the current strategic initiatives of Elanco?

• Executing key companion-animal launches. Through early 2024, Elanco consistently highlighted the importance of bringing delayed or pending pet-health products to market. Zenrelia became a major milestone after receiving U.S. Food and Drug Administration approval in May 2024. Management also positioned Credelio Quattro as a significant near-term launch opportunity. These products matter because they can improve growth, refresh the portfolio, and shift mix toward higher-value pet-health categories.

• Reshaping the portfolio through the announced aqua divestiture. In February 2024, Elanco announced an agreement to sell its aqua business to Merck Animal Health for $1.3 billion in cash, subject to regulatory approvals and customary closing conditions. Strategically, that move would narrow Elanco’s focus, simplify the operating footprint, and provide funds for debt reduction.

• Improving execution in the base business. Elanco’s public materials and earnings commentary have emphasized better commercial execution in the existing portfolio, especially in companion-animal categories. That includes stabilizing share where performance had been uneven, improving retail and distributor execution, and managing channel inventory more carefully.

• Driving productivity and margin improvement. Management has repeatedly pointed to manufacturing, procurement, portfolio simplification, and overhead discipline as levers for better profitability. This is especially important because Elanco’s product mix is broad and the company still carries the complexity of past acquisitions.

• Maintaining a meaningful farm-animal value proposition. Elanco continues to invest in cattle, swine, poultry, and other livestock categories where products can help producers improve economics, health outcomes, and operating consistency. In a tougher livestock environment, the company’s strategic task is to defend relevant categories without overinvesting in lower-return parts of the portfolio.

• Deleveraging the balance sheet. Since the Bayer Animal Health transaction, debt reduction has remained a strategic priority. This is not merely a finance housekeeping item. Lower leverage would improve flexibility for launch support, R&D, targeted business development, and overall resilience.

3. What is the business model of Elanco?

• What customers actually buy. Elanco sells regulated animal-health products that promise a measurable outcome: parasite prevention, disease treatment, pain relief, feed efficiency, herd health, or improved production economics. Companion-animal buyers often buy safety, convenience, and trust. Livestock buyers often buy return on investment.

• Recurring or repeat-driven versus one-time. Elanco’s revenue is transactional rather than subscription-based, but much of it is repeat-driven. Flea and tick control is seasonal or monthly. Chronic pet conditions can generate ongoing use. Livestock products often repeat by production cycle, herd, flock, or season. That makes the business commercially recurring even though revenue is recognized product by product.

• How pricing power works. Pricing power appears strongest in differentiated, branded companion-animal products, especially where veterinarians influence the choice and pet owners are reluctant to switch. It is generally weaker in mature livestock categories where buyers are more price-sensitive and the economic decision is tied directly to production margins.

• Why the business mix matters. The mix between pet health and farm animal matters a great deal. Companion-animal products usually offer better structural growth and, often, stronger margins. Farm animal can still be attractive, but it is more exposed to commodity cycles, producer economics, and regional disease patterns. Investors therefore tend to care not just about total revenue, but about where that revenue comes from.

• What drives gross margin, operating margin, and cash generation. Gross margin is influenced by product mix, manufacturing efficiency, supply reliability, procurement costs, and the degree of price competition. Operating margin depends on salesforce efficiency, launch spending, R&D levels, and overhead discipline. Cash generation is shaped by inventory management, receivables, and the fact that animal health is typically less capital-intensive than many heavy industrial businesses, even though it still requires disciplined manufacturing and quality systems.

• Revenue model. Elanco is fundamentally a product-sales business. It sells through veterinary, distributor, retail, e-commerce, and farm channels rather than through software subscriptions or usage-based pricing. The closest thing it has to recurring revenue is repeat purchase behavior built on brand trust, animal lifecycles, and preventive-care routines.

4. What products and/or services does Elanco sell?

Companion Animal

Elanco’s companion-animal portfolio includes parasiticides, dewormers, dermatology and pain products, and other veterinary therapies for dogs and cats. Important brands include Seresto, Advantage, Credelio, Interceptor Plus, Trifexis, and Galliprant. By mid-2024, Zenrelia had become an important new launch in canine dermatology. These categories are strategically important because they are tied to veterinary recommendation, pet-owner loyalty, and repeat purchasing.

Farm Animal

On the farm side, Elanco sells products for cattle, dairy, swine, poultry, and, until the announced aqua divestiture closes, aquaculture. The farm portfolio includes anti-infectives, parasiticides, feed additives, productivity enhancers, and selected vaccines. Brands such as Rumensin and Experior illustrate the company’s emphasis on producer economics and animal performance.

Which offerings appear most important

Companion-animal parasiticides and therapeutics appear to carry the greatest strategic importance because they support the company’s mix-improvement goals and generally offer better long-term growth characteristics. Mature farm-animal products remain important because they contribute scale, customer relationships, and cash generation. Elanco’s challenge is to balance those two realities rather than treating the portfolio as if every product line has the same growth profile.

5. What are the key competitors or peers of Elanco?

Competition is not uniform across Elanco’s portfolio. In consumer-facing pet parasiticides, branding and channel presence matter more. In veterinary therapeutics, clinical differentiation and prescriber trust matter more. In farm animal health, producer economics, regulatory positioning, and field support often matter as much as pure product attributes.

6. What is the marketing strategy of Elanco?

Elanco’s marketing strategy varies sharply by category. In companion-animal health, especially in parasiticides and other visible pet brands, marketing is an important differentiator. The company has to build awareness with pet owners, support veterinarians with clinical education, and win shelf or online visibility with retailers and e-commerce channels. Brands such as Seresto and Advantage are not sold purely on molecule-level science; they also depend on trust, convenience, and repeat consumer demand.

In prescription-oriented veterinary categories, Elanco relies more on scientific marketing, field education, and key-opinion-leader support than on mass advertising. In farm animal, marketing is more economics-driven: producers and integrators want evidence of performance, disease control, feed efficiency, or operational reliability. Trade promotion and distributor support also matter, especially where Elanco uses channel partners to reach fragmented customers.

Overall, marketing is a major strategic lever in consumer-facing pet health and more of a supporting capability in farm animal. That split mirrors the business model: the more the end user behaves like a consumer, the more brand building matters.

7. What are the key customer segments of Elanco?

• Veterinarians and veterinary clinics. These customers are central in companion-animal prescription products because they recommend, prescribe, and influence long-term product choice.

• Pet owners. End demand in many pet categories comes from owners, especially in over-the-counter flea and tick products and in therapies for chronic conditions.

• Distributors, retailers, and e-commerce channels. These intermediaries are important in getting products to market efficiently and shaping visibility, trade economics, and fulfillment speed.

• Livestock producers and integrators. In cattle, dairy, swine, poultry, and aquaculture, Elanco sells into professional production systems where purchase decisions are tied to animal performance and economics.

• Animal-health advisers and technical decision-makers. In livestock, veterinarians, nutritionists, and production specialists can strongly influence purchasing.

Elanco is diversified across companion animal and farm animal, but the strategic importance of the segments is not equal. Companion animal is generally the more attractive growth and margin pool. Farm animal remains important, but its economics are more cyclical and operationally linked to protein markets.

8. What is the sales model of Elanco?

Elanco uses a multi-channel sales model. In companion animal, prescription products typically move through veterinarians and veterinary distributors, supported by a direct field sales force and technical teams. Over-the-counter products, especially consumer-visible parasiticides, also move through retail and e-commerce channels. That means Elanco must manage both professional selling and consumer channel execution.

In farm animal, the sales model is more account-based. Elanco sells through direct relationships with producers, integrators, feed operations, and veterinarians, sometimes supplemented by distributors. The sales effort tends to be more consultative and economics-oriented than in consumer pet channels.

This channel structure affects growth and pricing. Direct veterinary relationships provide better product feedback and clinical influence. Retail and distributor channels provide scale but can weaken customer intimacy and put more pressure on trade terms. For consultants, this creates natural project areas in salesforce sizing, key-account management, distributor strategy, omnichannel design, and pricing governance.

9. In what geographies does Elanco operate?

As of 2023, Elanco operated in more than 90 countries. The United States is one of its most important markets, but the company has broad international exposure across Europe, Latin America, and Asia-Pacific. That geographic spread reflects the nature of animal health: local registration, local disease conditions, and local production systems matter, so the business cannot be run as a purely centralized export model.

Elanco’s footprint includes a global commercial organization as well as manufacturing, regulatory, quality, and research capabilities distributed across major regions. Greenfield, Indiana is the corporate headquarters, but the operating footprint extends well beyond the U.S. through facilities and teams inherited from legacy Elanco and Bayer Animal Health operations.

Geographic breadth diversifies revenue but also adds complexity. Elanco must handle multiple regulatory regimes, currency exposures, country-specific labeling, regional supply planning, and different patterns of veterinary and livestock demand.

10. Who are the owners of Elanco?

Elanco is a publicly traded company listed on the New York Stock Exchange. As of its 2024 proxy disclosures, the company did not have a controlling shareholder. Ownership is primarily institutional. Large holders reported in SEC ownership filings around 2024 included major asset managers such as The Vanguard Group and BlackRock, although exact positions can change over time.

Eli Lilly fully separated Elanco in 2019, so Elanco is no longer controlled by its former parent.

11. How is Elanco organized?

Officially, Elanco reports one reportable segment: Animal Health. That is the legal and financial reporting view. Practically, however, management and investors often think about the company in two broad operating portfolios: Pet Health and Farm Animal. That distinction matters because the economics, channels, and growth rates are different.

Operationally, Elanco appears to be organized through a mix of global functions and regional commercial teams. Shared capabilities include research and development, regulatory affairs, manufacturing, quality, supply chain, finance, and corporate functions. Commercial execution is then adapted by species, product category, geography, and channel.

The key analytical point is that SEC segment reporting understates the business-model differences inside Elanco. A consumer-facing flea-and-tick brand and a cattle feed additive may sit in the same reportable segment, but they behave very differently commercially and strategically.

12. How does Elanco operate?

Elanco operates as a global animal-health product company. The value chain begins with discovering or licensing compounds, formulations, and biologics; running veterinary trials and regulatory studies; gaining approvals; manufacturing finished goods; and distributing them through veterinary, retail, and livestock channels. After sale, the company also has to manage safety monitoring, quality assurance, technical support, and lifecycle management.

Day to day, performance depends on a few operational disciplines. The company must forecast demand accurately for seasonal pet products and for livestock cycles that can shift with weather, disease pressure, and producer economics. It must manage manufacturing quality and batch release carefully because veterinary products are regulated and often have limited shelf life. It must also balance many stock keeping units across multiple countries and package configurations.

Operational bottlenecks in this industry usually come from regulatory delays, plant reliability, supply interruptions, inventory imbalances, and poor launch execution. Elanco’s public priorities suggest that simplifying the portfolio and improving productivity are meant in part to reduce those operational frictions.

13. What are the growth opportunities for Elanco?

• New pet-health launches. The clearest growth opportunity is successful commercialization of late-stage and newly approved companion-animal products, especially where they expand Elanco’s presence in higher-growth therapeutic categories.

• Better monetization of existing pet brands. Elanco can still grow by improving execution around established brands such as Seresto, Advantage, Credelio, and Galliprant through better channel management, lifecycle work, and international expansion.

• Portfolio sharpening. If the announced aqua divestiture closes, Elanco would have an opportunity to operate as a more focused company with clearer resource allocation and potentially better margin structure.

• Farm-animal solutions tied to economics and sustainability. Producers continue to seek health and productivity tools that improve feed efficiency, operational consistency, and compliance with evolving environmental and stewardship expectations.

• Productivity-led profit growth. Not all growth has to come from new products. Manufacturing efficiency, procurement, SKU reduction, and working-capital improvement can all expand earnings and cash flow.

• Selective business development. Once balance-sheet flexibility improves, Elanco could pursue smaller capability-building deals or partnerships rather than large transformative acquisitions.

Main constraints include regulatory timing, competitive intensity in companion animal, generic or private-label pressure in some categories, livestock-market cyclicality, foreign exchange, and the balance-sheet burden created by past M&A.

14. What is the history of Elanco?

• 1954: Elanco began as the animal health business of Eli Lilly.

• 2018: Eli Lilly took Elanco public in an initial public offering while still retaining control.

• 2019: Elanco became fully independent through its separation from Eli Lilly.

• 2019: Elanco acquired Aratana Therapeutics, adding companion-animal therapeutics and broadening its pet portfolio.

• 2020: Elanco closed the acquisition of Bayer Animal Health, a transformative deal that greatly increased its scale and added important pet brands such as Seresto and Advantage.

• 2021: Elanco acquired Kindred Biosciences, adding pipeline assets and strengthening its companion-animal innovation platform.

• 2024: Elanco announced an agreement to divest its aqua business to Merck Animal Health for $1.3 billion in cash, subject to closing conditions and approvals.

The modern Elanco story is therefore shaped less by its origins inside Lilly than by its post-spin portfolio moves: building scale through Bayer, adding selected pet-health innovation through bolt-ons, and then simplifying again through divestiture.

15. What are the key brands owned by Elanco?

Branding is far more important in Elanco’s companion-animal portfolio than in many of its farm-animal lines. In pet health, brand trust can directly influence repeat purchase and channel support. In farm animal, product economics and technical credibility usually matter more than consumer-style branding.

16. How does the supply chain of Elanco function?

Elanco’s supply chain is strategically important because the company sells regulated products across many countries, species, and dosage forms. Inputs include active pharmaceutical ingredients, biologic materials, excipients, packaging, and specialized components used in consumer pet products. Manufacturing can involve internal facilities as well as third-party partners, depending on product type.

From there, products move through a controlled network of quality release, warehousing, distribution, and channel replenishment. The supply chain must support veterinary clinics, distributors, retail accounts, e-commerce channels, and livestock customers. It also must handle country-specific packaging and registrations, which limits the ease of moving inventory around the world.

Reliability matters for strategic reasons. Missed supply in a seasonal flea-and-tick category can mean lost shelf space and lost consumer loyalty. Missed supply in livestock can disrupt production cycles and damage technical credibility with producers. That is why supply-chain execution, procurement discipline, inventory accuracy, and manufacturing uptime are more than back-office issues for Elanco.

17. What is the R&D strategy of Elanco?

R&D is an important part of Elanco’s strategy, but the company’s approach appears selective rather than sprawling. The priority is to put development resources behind products that can materially improve portfolio quality, especially in companion-animal categories where growth and margins are structurally better. That is one reason the company has put so much emphasis on assets such as Zenrelia and Credelio Quattro.

Elanco’s R&D model includes both internal development and external sourcing of innovation through acquisitions and partnerships. The acquisitions of Aratana and Kindred Biosciences show that Elanco is willing to buy pipeline assets and capabilities rather than relying only on internally discovered products.

In livestock, R&D is more targeted. The company appears to focus on products that solve clear producer problems, whether in health, productivity, or environmental performance. In animal health, successful R&D is not just lab science; it also requires field trials, species-specific evidence, regulatory navigation, manufacturing scalability, and commercial relevance. Elanco’s challenge is to convert R&D from a cost center into visible launch output.

18. What is the finance strategy of Elanco?

Elanco’s finance strategy since 2020 has been heavily shaped by the Bayer Animal Health acquisition. The balance sheet became a strategic constraint, so capital allocation has emphasized deleveraging, protecting liquidity, improving margins, and generating cash rather than returning large amounts of capital to shareholders. That makes finance a core part of corporate strategy, not just a reporting function.

The announced February 2024 sale of the aqua business to Merck Animal Health is the clearest example. If completed, the transaction would bring in $1.3 billion of cash and, based on management’s public comments, would primarily support debt reduction. That would give Elanco more flexibility to support launches, invest in higher-return R&D, and potentially pursue selective business development later.

Operationally, the finance strategy depends on better gross margin, disciplined spending, and tighter working-capital management. Elanco’s public metrics and messaging suggest that adjusted earnings, cash generation, and leverage are the most important financial proof points for the strategy.

19. What major acquisitions has Elanco made?

M&A has played an important role in Elanco’s evolution, although the company’s recent posture has shifted from expansion to portfolio refinement.

• Aratana Therapeutics (2019). This acquisition added companion-animal therapeutics and deepened Elanco’s exposure to pet health.

• Bayer Animal Health (closed 2020). This was the transformative deal. It materially increased Elanco’s scale, broadened geographic reach, and added major companion-animal brands such as Seresto and Advantage.

• Kindred Biosciences (2021). This deal added pipeline and development assets, including dermatology-related opportunities that became strategically important later.

As of 2024, the bigger strategic story was no longer acquiring for sheer scale. It was integrating what Elanco had bought, improving performance, and pruning the portfolio where needed. The announced aqua divestiture to Merck Animal Health in February 2024 shows that portfolio reshaping is now as important as acquisition-led growth. Because that transaction was only announced as of mid-2024, it should be treated as pending rather than completed.

20. How Companies Like Elanco Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These professionals include alums of McKinsey, Bain, BCG, and other top firms. Companies like Elanco use Umbrex when they need senior consulting talent with top-tier training, but do not need a full consulting team with the associated overhead. For an animal-health company balancing launches, portfolio simplification, manufacturing productivity, channel complexity, and debt reduction, that model can be especially useful.

• Launch PMO for new pet-health products. Build a focused launch office for products such as Zenrelia or future companion-animal therapies, covering market readiness, field execution, and post-launch dashboards.

• Companion-animal pricing and trade-spend optimization. Assess pricing architecture, trade terms, retailer economics, and promotion effectiveness across veterinary, retail, and e-commerce channels.

• Post-divestiture operating model redesign. Support organization, process, and cost redesign if the aqua-business sale closes, including transitional service planning and stranded-cost removal.

• Manufacturing and procurement productivity program. Identify margin-improvement opportunities across sourcing, plant footprint, batch planning, and SKU simplification.

• Working-capital and inventory improvement. Reduce inventory risk in seasonal parasiticides and improve forecast accuracy, service levels, and channel inventory visibility.

• Veterinary and farm-animal salesforce effectiveness. Rework territory design, call planning, key-account coverage, and incentive structures for both pet and livestock businesses.

• Portfolio strategy and brand prioritization. Help management decide where to invest behind legacy brands, where to harvest, and where to exit lower-return categories.

• R&D portfolio governance. Create stage-gate and resource-allocation frameworks to rank pipeline assets by clinical probability, strategic fit, launch value, and manufacturing complexity.

• Data, ERP, and reporting harmonization. Support finance, supply chain, and commercial-data integration across legacy Elanco and acquired businesses.

• M&A and separation support. Provide targeted help on diligence, integration, synergy tracking, separation planning, and value-capture for future bolt-ons or divestitures.